Human Acellular Vessel (HAV)
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Peripheral Artery Disease
Conditions
Peripheral Artery Disease
Trial Timeline
Dec 20, 2016 → Dec 1, 2023
NCT ID
NCT02887859About Human Acellular Vessel (HAV)
Human Acellular Vessel (HAV) is a phase 2 stage product being developed by Humacyte for Peripheral Artery Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02887859. Target conditions include Peripheral Artery Disease.
What happened to similar drugs?
8 of 20 similar drugs in Peripheral Artery Disease were approved
Approved (8) Terminated (2) Active (11)
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03005418 | Phase 2/3 | Active |
| NCT03183245 | Phase 3 | Completed |
| NCT02887859 | Phase 2 | Completed |
| NCT02644941 | Phase 3 | Completed |
Competing Products
20 competing products in Peripheral Artery Disease